Tenderwize
Retour à la recherche

Open-house rebate agreement for epinephrine nasal spray

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 33 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epinephrin (ATC-Code nach WHO: C01CA24) in der Darreichung Nasenspray

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The first submission deadline is fixed, and further deadlines are only available in a portal attachment not provided he...

Key participation documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') are referen...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing epinephrine in nasal spray form.
  • Open-House participation model with no individual negotiations and no exclusivity.
Afficher le résumé complet

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for epinephrine nasal spray (ATC C01CA24) in Germany. The contract is open to all interested pharmaceutical companies that meet and accept the stated participation conditions. No minimum purchase volume is guaranteed, no individual negotiations are conducted, and exclusivity is explicitly excluded. Participation documents must be obtained via DTVP after access approval, and submission is electronic via the portal communication function, not via the bidder tool. The notice is structured as a single lot, but the value is not stated.

Risques

The first submission deadline is fixed, and further deadlines are only available in a portal attachment not provided he...

Key participation documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') are referen...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the offered medicinal product.

Eligibility

  • The bidder must submit the completed declaration on the absence of exclusion grounds with the participation documents.

Administrative

  • The bidder must submit the declaration on Russia sanctions compliance using the specified form.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for epinephrine nasal spray

Single lot covering the conclusion of non-exclusive pharmaceutical rebate agreements under Section 130a(8) SGB V for epinephrine (WHO ATC C01CA24) in nasal spray form. The lot is an Open-House model, so any interested pharmaceutical company may participate if it meets and accepts the participation conditions. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volume are stated. Performance/place of performance is Germany, with Dresden and the federal states of Saxony and Thuringia mentioned in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Sep 2025 - Sep 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 30, 2026

Détails de la procédure

Date de publication
31 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
504345-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30